Symbole du gouvernement du Canada

Liens de la barre de menu commune

GlaxoSmithKline

Mémoires — GlaxoSmithKline

Note importante : Le contenu des mémoires et des résumés est de la seule responsabilité de la personne et / ou de l'organisation qui les a rédigés. L'affichage du contenu ne signifie pas que le groupe d'experts appuie ou approuve les propos énoncés. Les mémoires et les résumés sont affichés dans la langue dans laquelle ils ont été rédigés.

Soumissionnaire (s) : Clow, Dan

Résumé : By definition R&D (comprised of basic research, applied research and experimental development) is a subset of the broader term, innovation (which also includes commercialization). Canada has historically focused heavily on investing in early R&D elements but has neglected to adequately support the later elements including commercialization. This provides a likely explanation for why our world-leading investment in R&D (relative to GDP) has not delivered a reciprocal return on innovation and productivity. Instead of investing in innovation – we've been investing in R&D! We need to shift the focus, however, this doesn't necessarily mean shifting government funding out of the research pot since many of the necessary changes don't require a direct financial investment as much as they require that the right policy framework is in place to ensure that incentives to innovation are aligned and impediments are removed.

Version complète du mémoire : Version PDF